Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Mem. Inst. Oswaldo Cruz ; 117: e200444, 2022. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1375921

RESUMEN

There is no consensus on the diagnostic algorithms for many scenarios of Trypanosoma cruzi infection, which hinders the establishment of governmental guidelines in endemic and non-endemic countries. In the acute phase, parasitological methods are currently employed, and standardised surrogate molecular tests are being introduced to provide higher sensitivity and less operator-dependence. In the chronic phase, IgG-based serological assays are currently used, but if a single assay does not reach the required accuracy, PAHO/WHO recommends at least two immunological tests with different technical principles. Specific algorithms are applied to diagnose congenital infection, screen blood and organ donors or conduct epidemiological surveys. Detecting Chagas disease reactivation in immunosuppressed individuals is an area of increasing interest. Due to its neglect, enhancing access to diagnosis of patients at risk of suffering T. cruzi infection should be a priority at national and regional levels.

2.
Mem. Inst. Oswaldo Cruz ; 111(3): 218-221, Mar. 2016. tab, graf
Artículo en Inglés | LILACS | ID: lil-777373

RESUMEN

Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Enfermedad de Chagas/tratamiento farmacológico , Nitroimidazoles/farmacocinética , Tripanocidas/farmacocinética , Trypanosoma cruzi/efectos de los fármacos , Química Farmacéutica , Enfermedad de Chagas/metabolismo , Estudios de Seguimiento , Nitroimidazoles/administración & dosificación , Nitroimidazoles/sangre , Reacción en Cadena en Tiempo Real de la Polimerasa , Tripanocidas/administración & dosificación , Tripanocidas/sangre , Trypanosoma cruzi/aislamiento & purificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA